Healthcare Review: GW Pharmaceuticals, Galena Biopharma, Isis Pharmaceuticals, Novartis, Alexion Pharmaceuticals Print E-mail
By Staff and Wire Reports   
Tuesday, 17 June 2014 11:10
U.S. stocks traded little changed in choppy trading Tuesday, as investors weighed disappointing housing-market data against easing jitters over Iraq. The Dow Jones Industrial Average slipped nine points, or 0.1%, to 16772. The Dow was down as much as 48 points and up 29 points earlier in the session. That follows a similar back-and-forth session on Monday, when the Dow closed up five points, after being down 53 points and up 26 points. The S&P 500 index eased one point, or 0.1%, to 1937. The index was 0.7% below its June 9 record high close of 1951.27.

GW Pharmaceuticals ($GWPH) reports preliminary data on 27 children and young adults with treatment-resistant epilepsy who have been treated with its investigational cannabidiol product candidate Epidiolex for a period of 12 weeks. Of the 27 patients, nine have Dravet syndrome and the remaining 18 have treatment-resistant epilepsies with convulsive and/or non-convulsive siezures.The mean overall reduction in seizure frequency compared to baseline was 44%. The median overall reduction was 42%.At the end of 12 weeks, 48% of the patients achieved at least a 50% reduction in seizure frequency compared to baseline. 41% of the patients achieved at least a 70% reduction. 22% of the patients achieved at least a 90% reduction and 15% of the patients were seizure-free.

Galena Biopharma ($GALE) completes enrollment of the full 45-patient cohort for the Phase 2a clinical trial for GALE-301 (Folate Binding Protein (FBP) peptide immunotherapy). The two arms of the trial consist of HLA-A2-positive patients treated with the FBP peptide plus granulocyte macrophage-colony stimulating factor (GM-CSF) and an observational control group of HLA-A2-negative patients. After an initial induction series of six vaccinations given once per month, patients will receive booster inoculations at two subsequent six-month intervals. The primary objectives are to measure the immune response, time to recurrence and overall survival between treatment arms.

Isis Pharmaceuticals ($ISIS) earns its first milestone payment from its neurological disorder collaboration with Biogen (BIIB). The $10M payment was triggered by the validation of an undisclosed target.

The FDA designates Alexion Pharmaceuticals' ($ALXN) Soliris (eculizumab) an Orphan Drug for the neurologic disorder Myasthenia Gravis (MG). The company is currently enrolling patients in a multinational placebo-controlled registration trial of eculizumab in patients with refractory generalized MG.

Novartis ($NVS) submits its BLA to the FDA for its Breakthrough Therapy-designated meningitis B vaccine Bexsero (Multicomponent Meningococcal Group B Vaccine [recombinant, absorbed]). The vaccine helps protect adolescents and young adults from ages 10 - 25 against invasive meningococcal disease caused by serogroup B (meningitis B).




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter